{"id":"W4249692483","doi":"10.1016/j.clgc.2020.06.002","title":"Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Guardant Health; Janssen Pharmaceuticals; Janssen Biotech; Bristol-Myers Squibb Canada; EMD Serono; Genentech; Astellas Pharma; Eisai; Daiichi-Sankyo; Aileron Therapeutics; CTI Biopharma; ImmunoGen; Mirati Therapeutics; Bayer Fund; Five Prime Therapeutics; Acceleron; Clovis Oncology; TG Therapeutics; AstraZeneca; Novocure; Sanofi Genzyme; Takeda Pharmaceuticals U.S.A.; Immunocore; AbbVie; Karyopharm Therapeutics; Exelixis; MedImmune; Sanofi; Celgene; Novartis; Merck; GlaxoSmithKline; Roche; Foundation Medicine; Astellas Pharma US; American Society of Clinical Oncology; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Boston Biomedical; Pfizer; Amgen; Boehringer Ingelheim; Calithera Biosciences; Bayer; Sarah Cannon Research Institute","keywords":"Medicine; Internal medicine; Nivolumab; Renal cell carcinoma; Rash; Clinical endpoint; Regimen; Clear cell renal cell carcinoma; Progression-free survival; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cancer; Toxicity; Chemotherapy; Clinical trial; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003122174,0.0003377976,0.0008637258,0.00003973653,0.00008213537,0.00001187689,0.0002263852,0.0001226497,0.00006371921],"category_scores_gemma":[0.0001548194,0.0002178911,0.0001585316,0.00029142,0.0002170668,0.00007579164,0.0002095776,0.000606196,0.00001411347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001243283,"about_ca_system_score_gemma":0.0002353213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003599888,"about_ca_topic_score_gemma":0.00004075464,"domain_scores_codex":[0.9967268,0.0003302714,0.00124995,0.0008596306,0.0004864506,0.0003469734],"domain_scores_gemma":[0.9976743,0.0006822796,0.0004415534,0.0006757908,0.0001502393,0.0003757834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1885882,0.01002798,0.783223,0.00009120591,0.0001710602,0.0005775624,0.002554452,0.0002505885,0.0006813582,1.355374e-7,0.0007517854,0.01308265],"study_design_scores_gemma":[0.1091636,0.02171022,0.8656132,0.00008430656,0.000409887,9.348509e-7,0.0004880834,0.0001226974,0.001452808,0.000001056063,0.0007452162,0.0002080385],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951184,0.001198905,0.000003062348,0.0006703564,0.0001353522,0.001962743,0.0002878561,0.0000285715,0.0005947354],"genre_scores_gemma":[0.9983886,0.000249809,0.0002865654,0.0003626102,0.0003655199,0.0000344164,0.0001083683,0.00005355538,0.0001505698],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08239013,"threshold_uncertainty_score":0.8885339,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03801789324814368,"score_gpt":0.3212636307632831,"score_spread":0.2832457375151394,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}